SCHEMBL4286150

SCHEMBL4286150

COC(=O)/C=C/c1cc(C)c(Sc2ccc(F)cc2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
MAPT P10636 5/20 0.41
HPGD P15428 4/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ITGAL P20701 2/20 0.36
LMNA P02545 2/20 0.35
RHEB Q15382 1/20 0.35
NOS2 P35228 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286153 1.00 ALDH1A1 (0.41) ALDH1A1MAPTHPGDKDM4EMEN1
SCHEMBL4277853 0.87 PTGES (0.45) ALDH1A1MAPTHPGDKDM4EMEN1
SCHEMBL4277854 0.87 PTGES (0.45) ALDH1A1MAPTHPGDKDM4EMEN1
SCHEMBL13879620 0.81 ITGB2 (0.48) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL4281911 0.81 NPC1 (0.38) ALDH1A1MAPTMEN1KMT2AITGAL
SCHEMBL4281920 0.81 NPC1 (0.38) ALDH1A1MAPTMEN1KMT2AITGAL
SCHEMBL4280122 0.81 GAA (0.44) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL13879626 0.81 LMNA (0.41) ALDH1A1HPGDMEN1KMT2AHDAC1
SCHEMBL4280124 0.81 GAA (0.44) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL13879612 0.80 GAA (0.41) ALDH1A1MAPTHPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
EP-1943228-A2 INHIBITORS OF VIRAL REPLICATION Intermune, Inc. (US) 2008-07-16 EP disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 ALDH1A1 1500/4885MAPT 4203/4885HPGD 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.